Tenofovir disoproxil fumarate

Drug Profile

Tenofovir disoproxil fumarate

Alternative Names: Bis-POC-PMPA; GSK548470; PMPA-prodrug; Tenofovir DF; Tenozet; Viread

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
  • Developer Gilead Sciences; GlaxoSmithKline
  • Class Antiretrovirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B; HIV infections

Most Recent Events

  • 16 Aug 2017 Gilead Sciences completes a phase III trial for HIV-1 infections (In children, Combination therapy) in USA, Panama, Puerto Rico, United Kingdom (PO) (NCT00528957)
  • 20 Feb 2017 Blueclinical initiates enrolment in a phase II trial for HIV infections (Combination therapy) in Portugal (EudraCT2016-000346-61)
  • 01 Dec 2016 GlaxoSmithKline completes a phase III trial in Hepatitis B in China (NCT01300234)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top